Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician

Eric D. Hansen; Xiao Wang; Amy A. Case; Igor Puzanov; Tom Smith

doi:10.1016/j.jpainsymman.2018.05.015

Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician

Eric D. Hansen, Xiao Wang, Amy A. Case, Igor Puzanov, Tom Smith

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Immune checkpoint inhibitors (ICIs) have opened an exciting chapter in the treatment of patients with advanced cancer. For the palliative care clinician, however, ICIs present several new challenges, including new ways to define treatment success, as well as treatment-related toxicities that differ in nature and timing from traditional chemotherapy. In this article, we review the mechanism of action of ICIs, as well as selected published data supporting the efficacy of ICIs in patients with advanced cancer. In addition, we summarize existing data of ICI toxicity prevalence, patterns of severity, and timing of onset. Finally, we briefly review key principles from published guidelines on the management of ICI toxicities.

Original language	English (US)
Pages (from-to)	460-472
Number of pages	13
Journal	Journal of Pain and Symptom Management
Volume	56
Issue number	3
DOIs	https://doi.org/10.1016/j.jpainsymman.2018.05.015
State	Published - Sep 2018

Keywords

Immunotherapy
checkpoint inhibition
immune-related adverse events
toxicity

ASJC Scopus subject areas

Nursing(all)
Clinical Neurology
Anesthesiology and Pain Medicine

Access to Document

10.1016/j.jpainsymman.2018.05.015

Fingerprint Dive into the research topics of 'Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician'. Together they form a unique fingerprint.

Cite this

@article{df0276c1ec6444088ebb28055c5a0e67,

title = "Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician",

abstract = "Immune checkpoint inhibitors (ICIs) have opened an exciting chapter in the treatment of patients with advanced cancer. For the palliative care clinician, however, ICIs present several new challenges, including new ways to define treatment success, as well as treatment-related toxicities that differ in nature and timing from traditional chemotherapy. In this article, we review the mechanism of action of ICIs, as well as selected published data supporting the efficacy of ICIs in patients with advanced cancer. In addition, we summarize existing data of ICI toxicity prevalence, patterns of severity, and timing of onset. Finally, we briefly review key principles from published guidelines on the management of ICI toxicities.",

keywords = "Immunotherapy, checkpoint inhibition, immune-related adverse events, toxicity",

author = "Hansen, {Eric D.} and Xiao Wang and Case, {Amy A.} and Igor Puzanov and Tom Smith",

year = "2018",

month = sep,

doi = "10.1016/j.jpainsymman.2018.05.015",

language = "English (US)",

volume = "56",

pages = "460--472",

journal = "Journal of Pain and Symptom Management",

issn = "0885-3924",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician

AU - Hansen, Eric D.

AU - Wang, Xiao

AU - Case, Amy A.

AU - Puzanov, Igor

AU - Smith, Tom

PY - 2018/9

Y1 - 2018/9

N2 - Immune checkpoint inhibitors (ICIs) have opened an exciting chapter in the treatment of patients with advanced cancer. For the palliative care clinician, however, ICIs present several new challenges, including new ways to define treatment success, as well as treatment-related toxicities that differ in nature and timing from traditional chemotherapy. In this article, we review the mechanism of action of ICIs, as well as selected published data supporting the efficacy of ICIs in patients with advanced cancer. In addition, we summarize existing data of ICI toxicity prevalence, patterns of severity, and timing of onset. Finally, we briefly review key principles from published guidelines on the management of ICI toxicities.

AB - Immune checkpoint inhibitors (ICIs) have opened an exciting chapter in the treatment of patients with advanced cancer. For the palliative care clinician, however, ICIs present several new challenges, including new ways to define treatment success, as well as treatment-related toxicities that differ in nature and timing from traditional chemotherapy. In this article, we review the mechanism of action of ICIs, as well as selected published data supporting the efficacy of ICIs in patients with advanced cancer. In addition, we summarize existing data of ICI toxicity prevalence, patterns of severity, and timing of onset. Finally, we briefly review key principles from published guidelines on the management of ICI toxicities.

KW - Immunotherapy

KW - checkpoint inhibition

KW - immune-related adverse events

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=85049325324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049325324&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2018.05.015

DO - 10.1016/j.jpainsymman.2018.05.015

M3 - Article

C2 - 29792979

AN - SCOPUS:85049325324

VL - 56

SP - 460

EP - 472

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 3

ER -